Chairman
Solid Biosciences Inc. (SLDB)Board Member
Stoke Therapeutics, Inc. (STOK)Equibles does not estimate personal net worth.
Get an email with a short summary when Stoke Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get STOK alertsIan F. Smith is recorded as CEO and Board Member at Stoke Therapeutics, Inc. (STOK) and Chairman at Solid Biosciences Inc. (SLDB). The newest filing on record that lists Ian F. Smith as CEO and Board Member at Stoke Therapeutics, Inc. (STOK) is dated April 22, 2026. The newest filing on record that lists Ian F. Smith as Chairman at Solid Biosciences Inc. (SLDB) is dated April 23, 2026. Ian F. Smith was last confirmed as CFO at Vertex Pharmaceuticals Inc (VRTX) in a filing dated April 28, 2020. Stoke Therapeutics, Inc. reported in an 8-K filed October 6, 2025 that Ian F. Smith was appointed Chief Executive Officer, effective October 6, 2025. Stoke Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that Ian F. Smith was appointed Interim Chief Executive Officer, effective March 19, 2025. Stoke Therapeutics, Inc. reported in an 8-K filed September 20, 2023 that Ian F. Smith was appointed Class II director, effective September 19, 2023. The proxy statement of Stoke Therapeutics, Inc. reports total compensation of $27,031,655 for Ian F. Smith in fiscal 2025, including a base salary of $170,625. Disclosed compensation is on record for 4 fiscal years. Ian F. Smith has spoken on 3 earnings calls and 3 other investor events across 1 company, most recently for Stoke Therapeutics, Inc. on October 29, 2026. Stoke Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Solid Biosciences Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Stoke Therapeutics, Inc. includes Arthur Tzianabos (Chairman), Thomas E. Leggett (CFO), Thomas Leggett (CFO) and 5 others.
“On October 5, 2025, the Board of Directors (the "Board") of Stoke Therapeutics, Inc. (the "Company") appointed Ian F. Smith, who has been serving as the Company's Interim Chief Executive Officer since March 19, 2025, as the Company's permanent Chief Executive Officer and principal executive officer (the "Smith Appointment"), effective as of October 6, 2025 (the "Effective Date").”
“Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer ("Interim CEO").”
“I'll start with some highlights from our phase three study. To date, approximately 110 of 162 enrolled patients have completed their week 28 visit. This is the time point at which data for the primary endpoint of change in major motor seizure frequency is captured.”
“What can you say about how the trial is going that gives you confidence in achieving what you would need to achieve to get the product approved? thanks for the question and good morning everybody I do have to provide my safe harbor statement so you'd see our SEC filings for all the forward-looking statements are…”
“Starting with our Phase III Emperor study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of vasiribonurcin and its potential to change the course of Dravet syndrome by addressing the underlying genetic cause of this disease.”
“Yeah, so first of all, thank you for everybody joining us on the webcast and those that are in the room with us today. Just as stepping back, I've been on the board of Therapeutics for three years now and while I was on the board at Stoke Hale, so was an advisor to the company.”
“I'm looking forward to the Q&A session more. But let me give you a quick update. First of all, thank you for joining us this morning here in person and also online.”
Start not stated–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 22, 2026
Start not stated–2021-04-28
Last confirmed by a filing; no departure on record
Start not stated–2020-04-28
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Stoke Therapeutics, Inc. (STOK) | Chief Executive Officer | $170,625 | $27,031,655 |
| 2019 | Vertex Pharmaceuticals Inc (VRTX) | Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer | $75,192 | $1,451,840 |
| 2018 | Vertex Pharmaceuticals Inc (VRTX) | Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer | $850,000 | $4,626,134 |
| 2017 | Vertex Pharmaceuticals Inc (VRTX) | Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer | $848,077 | $5,936,236 |
